Drug intelligence / Profile preview

LSAM-TKIs

Development stage: Preclinical
Lead developer: NanOlogy
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Intratumoral

Overview

LSAM-TKIs is a preclinical-stage therapeutic program developed by NanOlogy, utilizing their proprietary Large Surface Area Microparticle (LSAM) technology. This platform involves the production of pure drug microparticles with a high surface area, which are then formulated into a sterile suspension for intratumoral injection. The goal of LSAM-TKIs is to deliver tyrosine kinase inhibitors (TKIs) directly into solid tumors, allowing for high local drug concentrations and sustained release while minimizing systemic toxicity. This approach aims to improve the therapeutic index of TKIs in the treatment of various solid tumors.

Other names: LSAM-TKIs for Sterile Suspension

Targets

Tyrosine kinase

Beyond the preview

Go deeper on LSAM-TKIs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LSAM-TKIs.

Explore the full profile